ROLE OF NON-DRUG THERAPIES OF METABOLIC SYNDROME: CHALLENGES AND PROSPECTS
https://doi.org/10.20996/1819-6446-2016-12-6-725-732
Abstract
Abdominal obesity (and the closely related metabolic syndrome) is one of the most common diseases in the world. The urgency of the problem of the progression of abdominal obesity is not only in its high prevalence, but also in the formation of a high risk of developing cardiovascular disease and diabetes type 2. The main reasons for the rapid development of obesity are considered high-calorie food (which includes not only the quantity but also the quality of edible products), sedentary lifestyle and genetic predisposition. Until now there are underway great controversies about the procedures of fast and trouble-free weight loss. There are many studies on the treatment of various components of metabolic syndrome. Despite a number of different pharmaceutical drugs developed for the treatment of abdominal obesity, non-drug therapies come first as well as the organization of the right way of life, which is difficult and sometimes impossible task for the clinician. One of the main reasons is the lack of time in doctor during outpatient consultations. To resolve this issue the role of "School of Health" is considered in order to effectively reduce the body weight of patients with metabolic syndrome and maintaining long-term results. It is expected that the implementation of the "School of Health" in the complex treatment of patients with metabolic syndrome will more broadly inform patients about their disease, improve the motivational and cognitive components of plants, and increase compliance to carry out the doctor's prescription. A review of the prevalence and root causes of abdominal obesity is presented, as well as analysis of the effectiveness of existing “Schools of Health” in the clinical practice for the treatment of various chronic diseases.
About the Authors
S. N. Strelkova
Moscow City Out-patient Clinic №210
Russian Federation
Russian Federation
Svetlana N. Strelkova - MD, Head of the Cardiology Department.
Kashirskoye shosse 57/1, Moscow, 115211
K. V. Ovsyannicov
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Konstantin V. Ovsyannicov - MD, Ph.D., Professor
Russian Federation
Konstantin V. Ovsyannicov - MD, Ph.D., Professor
N. I. Utkina
Moscow City Out-patient Clinic №210
Russian Federation
Utkina Natalya Ivanovna - MD, Internal Medicine Specialist
Russian Federation
Utkina Natalya Ivanovna - MD, Internal Medicine Specialist
References
1. Reaven G.M. Metabolic syndrome: pathophysiology and management of cardiovascular disease. Circulation. 2002;103(3):286-8.
2. Reaven G.M. Why a cluster is truly a cluster insulin resistance and cardiovascular disease. Clin.Chem. 2008;54(5):785-7.
3. Gheita T.A., El-Fishawy H.S., Nasrallah M.M., Hussein H. Insulin resistance and metabolic syndrome in primary gout. Int J Rheum Dis. 2012;15(6):521-5.
4. Kershaw E.E., Flier J.S. Adipose Tissue as an Endocrine Organ. J. of clinic.endocrin. and metab.- 2004.№89(6). - P. 2548-2556.
5. Kalinina A.M. Health education for patients as a factor in increasing the effectiveness of arterial hypertension control. Trudnyy Patsient. 2006;4(8):2-23. (In Russ.) [Калинина А.М. Школа здоровья для больных как фактор повышения эффективности контроля артериальной гипертонии. Трудный Пациент. 2006;4(8):2-23].
6. Chazova I.E., Sliver V.B. Metabolic syndrome. Kardiovaskulyarnaya Terapiya i Profilaktika. 2003;3:328. (In Russ.) [Чазова И.Е., Мычка В.Б. Метаболический синдром. Кардиоваскулярная Терапия и Профилактика. 2003;3:32-8].
7. Ford E.S., Giles W.H., Mokdad A.H. et al. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27(10):2444-9.
8. Butrova S.A. Metabolic syndrome: pathogenesis, clinical features, diagnosis, treatment approaches. Russkiy Meditsinskiy Zhurnal. 2001;2(9):56-60. (In Russ.) [Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Русский Медицинский Журнал. 2001;2(9):56-60].
9. Mikhalevich S.I., Eshchenko A.V. Obstetric problems in patients with metabolic syndrome. Meditsinskie Novosti. 2011;6:19-22. (In Russ.) [Михалевич С.И., Ещенко А.В. Акушерские проблемы у пациенток с метаболическим синдромом. Медицинские Новости. 2011;6:19-22].
10. Aliyeva N.A. Features endocrine status of adolescent girls with obesity of various origins. Vestnik Volgogradskogo Gosudarstvennogo Meditsinskogo Universiteta. 2007;(1):26-9. (In Russ.) [Алиева Н. А. Особенности эндокринного статуса девушек-подростков с ожирением различного генеза. Вестник Волгоградского Государственного Медицинского Университета. 2007;(1):26-9].
11. Kazeka G.R. Metabolic syndrome. Novosibirsk: Siberian University Press; 2000. (In Russ.) [Казека Г.Р. Метаболический синдром. Новосибирск: Сибирское университетское издательство; 2000].
12. Zhuravlev O.V., Romantsov E.B., Babtsev A.F., eds. The metabolic syndrome in children and adolescents: a tutorial. Blagoveshchensk: Bukvits; 2012. (In Russ.) [Журавлев О.В., Романцов Е.Б., Бабцев А.Ф., ред. Метаболический синдром у детей и подростков: учебное пособие. Благовещенск: Буквиц; 2012].
13. Aneja A., El-Atat F., McFarlane S.L. et. al. Hypertension and obesity. Recent Prog Horm. Res. 2004;59:169-205.
14. Peterson L.R., Herrero P., Schechtman K.B. et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191-6.
15. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total cardiovascular disease mortality in middle - aged men. JAMA. 2002;288:2709-16.
16. Mamedov M.N. According to the materials of the I International Congress on prediabetes and metabolic syndrome. Arterial'naya Gipertenziya. 2005; 11 (3): 11-3. (In Russ.) [Мамедов М.Н. По материалам I Международного конгресса по предиабету и метаболическому синдрому. Артериальная Гипертензия. 2005;11(3):11-3].
17. Dedov I.I. Academician Dedov interview. Sakharnyy Diabet. 2011;1:12-4. (In Russ.) [Дедов И.И. Интервью академика Дедова. Сахарный Диабет. 2011;1:12-4].
18. Kolopkova T.A., Blinova V.V., Skvortsov Y.I., Subbotina V.G. Metabolic syndrome X pandemic of the XXI century. Saratovskiy Nauchno-Meditsinskiy Zhurnal. 2008;4(3):130-4. (In Russ.) [Колопкова Т.А., Блинова В.В., Скворцов Ю.И., Субботина В.Г. Метаболический синдром Х-пандемия ХХI века. Саратовский Научно-Медицинский Журнал. 2008;4(3):130-4].
19. Bubnova M.G. Obesity: Causes and mechanisms of increase in body weight, approaches to correction. Consilium Medicum. 2005;(5):11-9. (In Russ.) [Бубнова М.Г. Ожирение: причины и механизмы нарастания массы тела, подходы к коррекции. Consilium Medicum. 2005;(5):11-9].
20. Mamedov M.N., Oganov R.G. Epidemiological aspects of the metabolic syndrome. Kardiologiia. 2004;(9):4-8 (In Russ.) [Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология. 2004;(9):4-8].
21. Drapkina O.M., Korneeva O.N., Chernova E.M., Popova I.R. Obesity and non-alcoholic fatty liver disease. Rossiyskie Meditsinskie Vesti. 2012;17(3):19-24. (In Russ.) [Драпкина О.М., Корнеева О.Н., Чернова Е.М., Попова И.Р. Ожирение и неалкогольная жировая болезнь печени. Российские Медицинские Вести. 2012; 17(3):19-24].
22. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-71.
23. Yavelov I.S. Sudden cardiac death in the metabolic syndrome. Trudnyy Patsient. 2012;6:22-4. (In Russ.) [Явелов И.С. Внезапная сердечная смерть при метаболическом синдроме. Трудный Пациент. 2012;6:22-4].
24. Empana J-P., Duciemetiere P., Balkau B., Jouve X. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. Eur Heart J. 2007;9:1149-54.
25. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-78.
26. Shalnova S.A., Deev A.D., Oganov R.G., Shestov D.B. Role in systolic and diastolic blood pressure for prediction of mortality from cardiovascular disease. Kardiovaskulyarnaya Terapiya i Profilaktika. 2002;1:415. (In Russ.) [Шальнова С.А., Деев А.Д, Оганов Р.Г., Шестов Д.Б. Роль систолического и диастолического артериального давления для прогноза смертности от сердечно-сосудистых заболеваний. Кардиоваскулярная Терапия и Профилактика. 2002;1:4-15].
27. Schmidt M.I., Duncan B.B., Bang H. et al. Identifying individuals at high'risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005;8:2013-8.
28. Selvin E., Coresh J., Golden S.H. et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005;165(16):1910-6.
29. Fontbonne A, Eschwege E et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 1-yeas follow uh of the Paris Prospective Study. Diabetologia. 1989;32:300-4.
30. Mychka V.B., Bogieva R.M., Chazova I.E. Acarbose - a means of preventing multiple cardiovascular risk factors of the metabolic syndrome. Klinicheskaya Farmakologiya i Terapiya. 2003;12(2):80-5. (In Russ.) [Мычка В.Б., Богиева Р.М., Чазова И.Е. Акарбоза – средство профилактики множественных сердечно-сосудистых факторов риска метаболического синдрома. Клиническая Фармакология и Терапия. 2003;12(2):80-5].
31. Grundy S.M. Obesity, Metabolic Syndrome and Cardiovascular Disease. J Clin Endocrinol Metab. 2004;89:2595-600.
32. Ivashkin V.T., Drapkina O.M., Korneeva O.N. Clinical variants of metabolic syndrome. Moscow: Medical Information Agency; 2012. (In Russ.) [Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. Москва: Медицинское Информационное Агенство; 2012].
33. Malik S., Wong N.D., Franklin S.S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-50.
34. Stern M.P., Williams K., Gon-zalez-Villalpando C. et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676-81.
35. Berezina A.V., Belyayeva O.D., Berkovich O.A., et al. Quality of life in patients with abdominal obesity in reducing body weight through diet and physical exercise. Profilakticheskaya i Klinicheskaya Meditsina. 2011;39(2):23-30. (In Russ.) [Березина А.В., Беляева О.Д., Беркович О.А., и др. Качество жизни у больных абдоминальным ожирением при снижении веса тела с помощью диеты и физических тренировок. Профилактическая и Клиническая Медицина. 2011;39(2): 23-30].
36. Fontana L., Eagon J.C., Trujillo M.E., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010-3.
37. Hamdi O., Porramaticul S., A-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr. Diabetes Rev. 2006;2(4):367-73.
38. Adasheva T.V., Demicheva O.J. Metabolic syndrome - the basis of pathogenetic therapy. Lechashchiy Vrach. 2003; 10: 24-8. (In Russ.) [Адашева Т.В., Демичева О.Ю. Метаболический синдром – основы патогенетической терапии. Лечащий Врач. 2003;10:24-8].
39. Blagosklonnaya Y.V., Shlyakhto E.V., Krasil'nikova E.I. Metabolic cardiovascular syndrome. Russkiy Meditsinskiy Zhurnal. 2001;9(2):67-70. (In Russ.) [Благосклонная Я.В., Шляхто Е.В., Красильникова Е.И. Метаболический сердечно-сосудистый синдром. Русский Медицинский Журнал. 2001;9(2):67-70].
40. Drapkina O.M., Korneeva O.N., Chernova E.M. Epicardial fat and non-alcoholic fatty liver disease. Serdtse. 2012; 11 (4): 13-5. (In Russ.) [Драпкина О.М., Корнеева О.Н., Чернова Е.М. Эпикардиальный жир и неалкогольная жировая болезнь печени. Сердце. 2012; 11(4):13-5].
41. Calabro P., Yeh. E.T. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem. 2007;42:63-91.
42. Correa C. The patents from position of nation health. Essential Drug Monitor. 2001;28&29:36.
43. Dedov I.I., Melnichenko G.A., Romantsova T.I. Obesity. Moscow: MIA; 2004. (In Russ.) [Дедов И.И., Мельниченко Г.А., Романцова Т.И. Ожирение. Москва: МИА; 2004].
44. Shestakova M.V., Dedov I.I. Ways of prevention of diabetes type 2. Diabetes and cardiovascular disease. Sakharnyy Diabet. 2002;(4):34-8. (In Russ.) [Шестакова М.В., Дедов И.И. Пути профилактики сахарного диабета 2го типа. Сахарный диабет и сердечно-сосудистые заболевания. Сахарный Диабет. 2002;(4):34-8].
45. Borch-Jolinsen K. The new classification of diabetes mellitus and IGT: a critical approach. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:86-93.
46. Liese A.D., Majer-Davis E.J., Haffner S.M. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998;20:157-72.
47. Edvin A.M., Gale E. Should we dump the metabolic syndrome?: Yes. BMJ. 2008;336:6401.
48. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: jointstatement from the American Diabetes Association and the European Association for the Stady of Diabetes. Diabetes Care. 2005;28(9):2289-304.
49. Dedov I.I., Butrova S.A. Savelieva L.V. The efficacy of motivational training obese patients. Ozhirenie i Metabolizm. 2004;(2):25-9. (In Russ.) [Дедов И.И., Бутрова С.А., Савельева JI.B. Эффективность мотивационного обучения больных ожирением. Ожирение и Метаболизм. 2004;(2): 25-9].
50. Bolton-Smith C., Woodward M. Dietary composition and fat to sugar rations in relation to obesity. Int J Obes. 1994;18:820-8.
51. Valensi P. All in one. Monde Moderne (Franse). 2004:71-110;184-209.
52. Mamedov M.N. Guidelines for the diagnosis and treatment of metabolic syndrome. Moscow: Multiprint; 2005. (In Russ.) [Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. Москва: Мультипринт; 2005].
53. Ballor D.L., Poehlman E.T. Exercise-training enhances fat-free mass divservation during diet-induced weight loss: a meta-analytical finding. Int J Obes Relat Metab Disord. 1994;18:35-40.
54. Bjorntorp P. Evolution of the understanding of the role of exercise in obesity and its complications. Int J Obes Relat Metab Disord. 1995;19(Suppl 4):1-4.
55. Tereshchenko I.V. Endocrine disorders in boys and girls during puberty. Moscow: Soyuzmedinform; 1991. (In Russ.) [Терещенко И.В. Эндокринные расстройства у юношей и девушек в пубертатном периоде. Москва: Союзмединформ; 1991].
56. Tsaregorodcev G.I., ed. Philosophical and socio-hygienic aspects of teaching about health. Moscow: Meditsina; 1975. (In Russ.) [Царегородцев Г.И., ред. Философские и социально-гигиенические аспекты учения о здоровье. Москва: Медицина;1975].
57. Agras W.S., Kraemer H.C., Berkowitz R.I. et al. Does a vigorous feeding style influence early development af adiposity? J Pediatr. 1987;110:799-804.
58. Astrup A., Buemann B., Western P., et al., Obesity as an adaptation to a high fat diet: evidence from a cross-sectional study. Am J Clin Nutr. 1994;59:350-5.
59. Yeganyan R.A., Kalinina A.M. School of Health. Overweight and obesity. Moscow: Geotar Media; 2010. (In Russ.) [Еганян Р.А., Калинина А.М. Школа здоровья. Избыточная масса тела и ожирение. Москва: Геотар-Медиа; 2010].
60. Birketvedt G.S., Florholmen J., Sundsfjord J., et al. Behavioral and neuroendocrine characteristics of the night-eating syndrome. JAMA. 1999;282(7):657-63.
61. Bandini L.G., Schoeller D.A., Dietz W.H. Energy expenditure in obese and non obese adolescents. Pediatr Res. 1990;27:198-203.
62. Grundy S.M., Clee-man J.I., Daniels S.R. et al. Diagnosis-and Management of the Metabolic Syndrome. Circulation. 2005;112(17):2735-52.
63. Mkrtumian A.M., Podachina S.V. A comprehensive approach to the treatment of obesity. Effektivnaya Farmakoterapiya v Endokrinologii. 2007;(1):12-7. (In Russ.) [Мкртумян А.М., Подачина С.В. Комплексный подход в лечении ожирения. Эффективная Фармакотерапия в Эндокринологии. 2007;(1):12-7].
64. Vertkin A.L., Arinina E.N., Morgunov L.Y., et al Metabolic syndrome and hypogonadism in men:. Real interaction, approaches and pharmacotherapy. Therapevt. 2006;11-12:59-66. (In Russ.) [Верткин А.Л., Аринина Е.Н., Моргунов Л.Ю., и др. Метаболический синдром и гипогонадизм у мужчин: реальные взаимодействия, подходы и фармакотерапия. Терапевт. 2006;11-12:59-66].
65. Hansen D., Toubro S., Stock M. et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23(10):1016-24.
66. Ackroff K., Sclafani A. Effects of the lipase inhibitor orlistat on intake and preference for dietary fat in rats. Am J Physiol. 1996;271(1 Pt2):48-54.
67. Chazova I.E., Mychka V.B. Metabolic syndrome. Kardiovaskulyarnaya Terapiya i Profilaktika. 2003;3:32-8. (In Russ.) [Чазова И.Е., Мычка В.Б. Метаболический синдром. Кардиоваскулярная Терапия и Профилактика. 2003;3:32-8].
68. Chazova I.E., Mychka V.B. Metabolic syndrome. Moscow: Media Medica; 2004. (In Russ.) [Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва: Media Medica; 2004].
69. Podobed V.M. Metabolic syndrome: etiology, pathogenesis, diagnosis, treatment. Zdravookhranenie. 2005;4:42-7. (In Russ.) [Подобед В.М. Метаболический синдром: этиология, патогенез, диагностика, лечение. Здравоохранение. 2005;4:42-7].
70. Starkova N.T., Dvoryashina I.V. The metabolic syndrome is insulin resistance: the basic concept and effect. Ter Arkhiv. 2004;10:54-8. (In Russ.) [Старкова Н.Т., Дворяшина И.В. Метаболический синдром инсулинорезистентности: основная концепция и следствие. Терапевтический Архив. 2004;10:54-8].
71. Oganov R.G., Mamedov M.N., ed. School for the diagnosis and treatment of metabolic syndrome. Moscow: Meditsinskaya Knoga; 2007. (In Russ.) [Оганов Р.Г., Мамедов М.Н., ред. Школа по диагностике и лечению метаболического синдрома. Москва: Медицинская Книга; 2007].
72. Belostotskii A.V., Vinokurov V.G., Allenov A.M. Organization of interaction of health centers and offices in Moscow prevention. Byulleten 'Natsional'nogo Nauchno-issledovatel'skogo Instituta Obshchestvennogo Zdorov'ya Imeni N.A. Semashko. 2014;(1):43-6. (In Russ.) [Белостоцкий А.В., Винокуров В.Г., Алленов А.М. Организация взаимодействия центров здоровья и отделений профилактики Москвы. Бюллетень Национального Научно-исследовательского Института Общественного Здоровья Имени Н.А. Семашко. 2014;(1):43-6].
73. Ametov A.S. Obesity is an epidemic of the XXI century. Ter Arkhiv. 2002;74(10):5-7. (In Russ.) [Аметов А.С. Ожирение эпидемия XXI века. Терапевтический Архив. 2002;74(10):5-7].
74. Patient education program with diabetes. Experience School psychophysical self-regulation of the Russian Diabetes Association. Moscow: KUbK-a; 1996. (In Russ.) [Программа обучения пациентов с сахарным диабетом. Опыт работы Школы психофизической саморегуляции при Российской Диабетической Ассоциации. Москва: КУбК-а; 1996].
75. Oganov R.G., eds. School for patients with arterial hypertension. Information handbook for doctors. Moscow: GNITSPM; 2002. (In Russ.) [Оганов Р.Г., ред. Школа для пациентов с артериальной гипертонией. Информационно-методическое пособие для врачей. Москва: ГНИЦПМ; 2002].
76. Khokhlov A.L., Zhilina A.N., Lisenkova L.A. Comprehensive analysis of the effectiveness of atorvastatin in the correction of metabolic syndrome. Russkiy Meditsinskiy Zhurnal. 2007;6:501. (In Russ.) [Хохлов А.Л., Жилина А.Н., Лисенкова Л.А. Комплексный анализ эффективности применения аторвастатина в коррекции метаболического синдрома. Русский Медицинский Журнал. 2007;6:501]
77. Oganov R.G. (eds.), Eganyan R.A. School of Health. Overweight and obesity. Guidelines for doctors. Moscow: GEOTAR-Media, 2010. (In Russ.) [Оганов Р.Г. (ред.), Еганян Р.А. Школа здоровья. Избыточная масса тела и ожирение. Руководство для врачей. Москва: ГЭОТАР-Медиа, 2010].
Review
For citations:
Strelkova S.N., Ovsyannicov K.V., Utkina N.I. ROLE OF NON-DRUG THERAPIES OF METABOLIC SYNDROME: CHALLENGES AND PROSPECTS. Rational Pharmacotherapy in Cardiology. 2016;12(6):725-732. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-6-725-732
Views:
880
Email this article 